Medikinet Xl

Methylphenidate Hydrochloride, the active ingredient in Medikinet XL, is a central nervous system stimulant presented as an extended‑release tablet for oral use. It treats attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults.

GNH USA supplies Medikinet XL as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medikinet XL, a central nervous system stimulant, is indicated for conditions involving dysregulated attention and wakefulness.

- ADHD (children and adolescents): improves attention, reduces hyperactivity and impulsivity. - ADHD (adults): enhances focus and decreases impulsive behavior. - Narcolepsy: reduces excessive daytime sleepiness and improves wakefulness.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: abdominal discomfort or nausea. - Increased heart rate: mild tachycardia. - Anxiety: heightened nervousness or restlessness.

Serious or Rare Side Effects: - Arrhythmia: irregular heart rhythm that may require medical attention. - Severe hypertension: markedly elevated blood pressure. - Psychosis: hallucinations or delusional thoughts. - Seizures: convulsive episodes in susceptible individuals. - Allergic reaction: rash, swelling, or anaphylaxis. - Priapism: prolonged painful erection in males.

Before initiating therapy, consider the following precautions: - Cardiovascular assessment: evaluate heart disease and monitor blood pressure. - Psychiatric history: watch for new or worsening mood or psychotic symptoms. - Growth monitoring: regularly track height and weight in pediatric patients. - Abuse potential: use only as prescribed and avoid non‑medical sharing. - Concomitant MAO inhibitors: avoid use within 14 days of each other. - Store at ambient temperature: keep in the original pack, protect from moisture.

Methylphenidate may interact with several drug classes. Review the following interactions:

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Sympathomimetic agents: additive cardiovascular stimulation. - Tricyclic antidepressants: increased risk of arrhythmia.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors: may raise methylphenidate plasma levels. - Antacids: can alter gastrointestinal absorption. - Alcohol: may enhance central nervous system stimulation.